HoyoungMaengMD

Oncology • Bethesda, MD

Clinical Director, Vaccine Branch, CCR, NCI, NIH

Join to view full profile

Dr. Maeng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maeng's full profile

Already have an account?

Office
10 Center Dr Room 3B37
MSC 1578
Bethesda, MD 20892
Phone+1 240-781-3253

Fax+1 301-480-4983

Education & Training

Yonsei University College of MedicineClass of 1998
University of Texas M.D. Anderson Cancer CenterPost-Doctoral Fellowship, Research Fellowship
University of Texas M.D. Anderson Cancer CenterFellowship, Leukemia

Certifications & Licensure

MD State Medical License 2016 - 2025
DC State Medical License 2015 - 2016
MA State Medical License 2015 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Dr. Moon scholarship Yonsei Univ College of Medicine alimni Association. 2012
AACR-MedImmune fellowship AACR, 2007
ASH Travel Award ASH, 2007

Clinical Trials

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults Start of enrollment: 2009 Jun 29
Completed
Phase 1
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer Start of enrollment: 2009 May 11
Completed
Phase 1
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Start of enrollment: 2013 Mar 04
Completed
Phase 1
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer Start of enrollment: 2015 Jul 10
Terminated
Phase 2
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 Start of enrollment: 2015 May 12
Completed
Phase 2
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer Start of enrollment: 2024 May 14
Suspended
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization.
William Becker, Purevdorj B Olkhanud, Noriko Seishima, Paloma A Moreno, Katherine C Goldfarbmuren
Journal for Immunotherapy of Cancer. 2024-07-01
4 citations
Revealing the Heterogeneity of the Tumor Ecosystem of Cholangiocarcinoma through Single-Cell Transcriptomics.
Jihye L Golino, Xin Wang, Hoyoung M Maeng, Changqing Xie
Cells. 2023-03-10
13 citations
MPAsoftware enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays.
Joshua A Welsh, Bryce Killingsworth, Julia Kepley, Tim Traynor, Sean Cook
Cell Reports Methods. 2022-01-24

Lectures

Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-ri...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

National Cancer Institute Stage D0 Prostate Cancer Vaccine Clinical TrialDecember 31st, 2019
New Vaccine Could Delay ADT Use in Stage D0 Prostate CancerDecember 30th, 2019

Professional Memberships

American Association for Cancer Research - AACR
Member
American Society of Clinical Oncologists - ASCO
Member
American College of Physicians - ACP
Member
Society for Immunotherapy of Cancer
Member
American Society of Clinical Oncology - ASCO
Member

Other Languages

Korean